IL18 and colitis: In a pivotal study, Tian Z et al. discovered that dosages of APS at 100, 200 and 500 mg/kg can impede the activation of the NLRP3 inflammasome, which leads to reduced production of IL-18 and IL-1β, culminating in therapeutic outcomes for DSS-induced colitis [39].